Undertaking for Non- applicability of reg 32 of sebi (lodr) regualtion 2015 for the quarter ended on 31st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Johnson Pharmacare Ltd has filed an undertaking with BSE confirming that SEBI's Regulation 32 (LODR) does not apply to the company for the quarter ended 31 December 2025. This regulation requires listed companies that have raised funds through public issues, rights issues, or preferential allotments to disclose how the proceeds are actually used versus the stated purpose. The company, through its Additional Director Mr. Rajender Parsad (DIN: 10871533), certifies that it did not issue any shares via rights issue, preferential allotment, or any other such route during the quarter, so the compliance requirement is not triggered. This is a routine regulatory communication dated 14 February 2026.
No material impact on shareholders or the stock. The filing simply confirms the company did not raise fresh capital from the market in Q3 FY26, so no fund-utilisation disclosure is required.